A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission. Methods We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 micromol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point. Results Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment includes prednisone, cyclophosphamide, or methotrexate.237,238,245”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [245]
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Self-citationWegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
FAUCI, A. S., HAYNES, B. F., KATZ, P., & WOLFF, S. M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-76 · Cited by 2,001
Short form 36 (SF36) health survey questionnaire: normative data for adults of working age.
Jenkinson, C., Coulter, A., & Wright, L. (1993) · BMJ · doi:10.1136/bmj.306.6890.1437 · Cited by 1,718
Falk, R. J., Terrell, R. S., Charles, L. A., & Jennette, J. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4115 · Cited by 1,261
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056
Self-citationSavige, J., Gillis, D., Benson, E., Davies, D., Esnault, V., Falk, R. J., Chris Hagen, E., Jayne, D., Charles Jennette, J., Paspaliaris, B., et al. (1999) · American Journal of Clinical Pathology · doi:10.1093/ajcp/111.4.507 · Cited by 884
Self-citationValidation of rheumatoid arthritis improvement criteria that include simplified joint counts
van Gestel, A. M., Haagsma, C. J., & van Riel, P. L. C. M. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k · Cited by 803
Research works printed but not linked: 10
- Jennette JC, 1989, Am J Pathol, 135, 921
- Hauer HA, 1998, Clin Exp Immunol, 112, 28
- 10.1002/(SICI)1096-9896(200002)190:3<349::AID-PATH524>3.0.CO;2-A · doi:10.1002/(sici)1096-9896(200002)190:3<349::aid-path524>3.0.co;2-a
- 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J · DOI · Paper page
- Jayne DR, 1995, QJM, 88, 127
- Luqmani RA, 1994, QJM, 87, 671
- Bacon PA, 1995, Clin Exp Rheumatol, 13, 275
- 10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q · doi:10.1002/1529-0131(199810)41:10<1835::aid-art16>3.0.co;2-q
- Szpirt WM, 1996, Int J Artif Organs, 19, 501
- 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F · DOI · Paper page
Cited by
Items 401–500 of 999
Pusey, C. D., & Tarzi, R. M. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s41598 · Cited by 43
“Reducing the doses of cyclophosphamide The CYCAZAREM (Cyclophosphamide vs azathioprine for early remission phase of vasculitis) study established that it was possible to switch from cyclophosphamide to azathioprine once remission was attained at 3–6 months, thereby reducing cyclophosphamide exposure.(56) The CYCLOPS (…”
BackgroundSelf-citationNeuropathies with Systemic Vasculitis
Collins, M. P., & Kissel, J. T. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-9491-7.50108-3 · Cited by 37
ANCA-Associated Glomerulonephritis: Risk Factors for Renal Relapse
Göçeroǧlu, A., Berden, A. E., Fiocco, M. F., Floßmann, O., Westman, K. W. A., Ferrario, F., Gaskin, G., Pusey, C. D., Hagen, E. C., Noël, L., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165402 · Cited by 31
“Patients were derived from two international multicenter randomized clinical European Vasculitis Society (EUVAS) trials: MEPEX and CYCAZAREM.[11,20] Inclusion criteria for both trials are described elsewhere.”
MethodInfluentialSelf-citationGopaluni, S., Floßmann, O., Little, M. A., O’Hara, P. V., Bekker, P. J., Jayne, D. R. W., & the European Vasculitis Society (2018) · Arthritis & Rheumatology · doi:10.1002/art.40776 · Cited by 31
Self-citationInterventions for renal vasculitis in adults
Walters, G. D., Willis, N. S., Cooper, T. E., & Craig, J. C. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003232.pub4 · Cited by 31
Cancer preceding Wegener's granulomatosis: a case-control study
松田, 恵., Mellemkjaer, L., Sorensen, I. J., Thomsen, B. S., Dreyer, L., & Baslund, B. (2009) · Lara D. Veeken · doi:10.1093/rheumatology/kep009 · Cited by 31
Current Status of Outcome Measure Development in Vasculitis
Merkel, P. A., Aydin, S. Z., Boers, M., Cornell, C., Di̇reskeneli̇, H., Gebhart, D. E., Hatemi, G., Luqmani, R. A., Matteson, E. L., Milman, N., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.131248 · Cited by 31
“For example, what constitutes a “complete” or “partial” remission? How long must a patient be followed in a trial before a response is established? Also needed are intermediate outcomes to (1) gauge an early response that is meaningful and predictive of longer-term outcomes; (2) determine partial responses, for exampl…”
BackgroundMethodCardiovascular involvement in primary systemic vasculitis
Mukhtyar, C. B., Brogan, P. A., & Luqmani, R. A. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.02.002 · Cited by 31
Sharma, A., Dogra, S., & Sharma, K. (2015) · Dermatologic Clinics · doi:10.1016/j.det.2015.03.012 · Cited by 31
Infections, connective tissue diseases and vasculitis.
Avčin, T., Canova, M., Guilpain, P., Guillevin, L., Kallenberg, C., Tincani, A., Tonon, M., Zampieri, S., & Doria, A. (2008) · PubMed · Cited by 32
Rituximab treatment of ANCA-associated vasculitis
Raffray, L., & Guillevin, L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1748597 · Cited by 35
“The CYCAZAREM trial [52,53] compared maintenance regimens of oral cyclophosphamide (3 vs.”
MethodGopaluni, S., Smith, R., Donna, G., Cahill, H., Broadhurst, E., Wallin, E. F., McClure, M., Chaudhry, A., & Jayne, D. R. W. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02761-6 · Cited by 34
Self-citationRodrigues, C. E. M., Callado, M. R. M., Nobre, C. A., Moura, F. E. A., Vieira, R. M. R. D. A., de Albuquerque, L. A. F., & Vieira, W. P. (2010) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042010000200005 · Cited by 30
Acute and Long-term Toxicity of Cyclophosphamide
Haubitz, M. (2007) · Cited by 30
Batu, E. D., & Özen, S. (2012) · Current Rheumatology Reports · doi:10.1007/s11926-011-0232-4 · Cited by 30
“once daily for maintenance therapy [51].”
Systemic Vasculitis: Still a Challenging Disease
Buhăescu, I., Covic, A. C., & Levy, J. B. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.04.018 · Cited by 30
Renal vasculitis--an update in 2004
Booth, A. D., Pusey, C. D., & Jayne, D. R. W. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh318 · Cited by 30
Self-citationPullerits, R., Ljevak, M., Vikgren, J., & Bokarewa, M. I. (2012) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2012.02747.x · Cited by 29
Puéchal, X., Iudici, M., Pagnoux, C., Cohen, P., Hamidou, M. A., Aouba, A., Lifermann, F., Ruivard, M., Aumaître, O., Bonnotte, B., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2021-002160 · Cited by 30
Molnár, A., Studinger, P., & Ledó, N. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.884188 · Cited by 33
Outcome of Thirty Patients with ANCA-Associated Renal Vasculitis Admitted to the Intensive Care Unit
Frausová, D., Brejníková, M., Hrušková, Z., Rihova, Z. J., & Tesař, V. (2008) · Renal Failure · doi:10.1080/08860220802353892 · Cited by 29
“Moreover, infection has been identified as the primary cause of death in patients with AAV in general,([20,21]) and admission to the ICU for an infectious complication was also connected with high mortality in patients with rheumatic diseases.”
BackgroundRisk Factors Associated with Relapse in Japanese Patients with Microscopic Polyangiitis
Wada, T., Hara, A., Arimura, Y., Sada, K., & Makino, H. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.110705 · Cited by 29
Newall, C., Schinke, S., Savage, C. O. S., Hill, S. L., & Harper, L. (2005) · Rheumatology · doi:10.1093/rheumatology/keh548 · Cited by 28
“No other studies have investigated functional capacity and health status in patients with ANCA-associated vasculitis, although it is well recognized that health status remains poor despite successful treatment of disease [7, 20].”
BackgroundMethodLong-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin
Floßmann, O., & Jayne, D. R. W. (2009) · Rheumatology · doi:10.1093/rheumatology/kep411 · Cited by 32
Self-citationCurrent Landscape of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Lally, L., & Spiera, R. (2014) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2014.09.003 · Cited by 31
Update in the Management of ANCA-Associated Vasculitis: Recent Developments and Future Perspectives
Samman, K. N., Ross, C., Pagnoux, C., & Makhzoum, J. (2021) · International Journal of Rheumatology · doi:10.1155/2021/5534851 · Cited by 32
“CYC CYCAZAREM trial (2003) [45] CYC vs.”
Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.26 · Cited by 28
Pathogenesis and treatment of ANCA-associated vasculitis—a role for complement
Noone, D. G., Hébert, D., & Licht, C. P. B. (2016) · Pediatric Nephrology · doi:10.1007/s00467-016-3475-5 · Cited by 28
How to induce remission in primary systemic vasculitis
Jayne, D. R. W. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2004.11.004 · Cited by 28
Self-citationGranulomatosis with Polyangiitis in Childhood
Twilt, M., Benseler, S. M., & Cabral, D. A. (2012) · Current Rheumatology Reports · doi:10.1007/s11926-012-0238-6 · Cited by 30
“following standard glucocorticoid and cyclophosphamide therapy for AAV, remission maintenance using either continuing oral cyclophosphamide or azathioprine was equally effective with respect to relapse rates (CYCAZAREM trial) [66].”
BackgroundNagasaka, K., Harigai, M., Hagino, N., Hara, A., Horita, T., Hayashi, T., Itabashi, M., Ito, S., Katsumata, Y., Kawashima, S., et al. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1500111 · Cited by 27
“In remission maintenance therapy of AAV, which one of the GCþ POCY and GCþ azathioprine (AZA) is useful? In comparison of GC+ POCY (control group) and GCþAZA (experimental group), one RCT [33] and one observational study [34] were identified (Supplementary Table 9b and Supplementary Figure 9a).”
BackgroundTherapeutic Strategies for Systemic Necrotizing Vasculitides
Guillevin, L., & Pagnoux, C. (2007) · Allergology International · doi:10.2332/allergolint.r-07-144 · Cited by 27
Brusselle, G. (2007) · Acta Clinica Belgica · doi:10.1179/acb.2007.016 · Cited by 27
“After 3 to 6 months of induction therapy of generalized WG, azathioprine can indeed be substituted for cyclophophamide when remission has been achieved (20).”
BackgroundOutpatient assessment of systemic vasculitis
Nataraja, A., Mukhtyar, C. B., Hellmich, B., Langford, C. A., & Luqmani, R. A. (2007) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2007.01.004 · Cited by 27
Itabashi, M., Takei, T., Yabuki, Y., Suzuki, H., Ando, M., Akamatsu, M., Yamazaki, M., Mitobe, M., Watanabe, Y., Mochizuki, T., et al. (2010) · Nephron Clinical Practice · doi:10.1159/000286346 · Cited by 27
Lee, P. Y., Adil, E. A., Irace, A. L., Neff, L. L., Son, M. B. F., Lee, E. Y., Pérez‐Atayde, A. R., & Rahbar, R. (2016) · The Laryngoscope · doi:10.1002/lary.26013 · Cited by 27
“A trial comparing azathioprine and methotrexate found them to be equipotent as maintenance therapy.(58,59) Recently, rituximab (monoclonal anti-CD20 antibody) is increasingly utilized for the treatment of GPA.”
BackgroundRenal Involvement in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Zonozi, R., Niles, J. L., & Cortazar, F. B. (2018) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2018.06.001 · Cited by 27
Beimler, J., & Andrássy, K. (2004) · Pediatric Nephrology · doi:10.1007/s00467-004-1553-6 · Cited by 27
Are There Different Forms of Life in the Antineutrophil Cytoplasmic Antibody Universe?
Hoffman, G. S., & Langford, C. A. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-9-200511010-00012 · Cited by 27
“treatment but diverged when 1 study stopped treatment (9, 10) (Figure).”
BackgroundResultMalignancies and cyclophosphamide exposure in Wegener's granulomatosis.
Bernatsky, S., Ramsey‐Goldman, R., & Clarke, A. E. (2008) · PubMed · Cited by 27
Guidelli, G. M., Tenti, S., Pascarelli, N. A., Galeazzi, M., & Fioravanti, A. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.03.005 · Cited by 26
Tesař, V., & Hrušková, Z. (2014) · Nephron Clinical Practice · doi:10.1159/000368569 · Cited by 27
Joh, K., Muso, E., Shigematsu, H., Nose, M., Nagata, M., Arimura, Y., Yumura, W., Wada, T., Nitta, K., Makino, H., et al. (2008) · Clinical and Experimental Nephrology · doi:10.1007/s10157-008-0052-7 · Cited by 26
“Treatment regimens used for induction and maintenance should therefore be based on clinical as well as pathological features [4–6].”
Cranial nerve palsy in Wegener’s granulomatosis – Lessons from clinical cases
Nowack, R., Wachtler, P., Kunz, J., & Rasmussen, N. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0121-1 · Cited by 26
Self-citationCurrent Therapies for ANCA-Associated Vasculitis
Lally, L., & Spiera, R. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-011514-023051 · Cited by 28
Therapie von Vaskulitiden und Vaskulopathien
Sunderkötter, C. H., & de Groot, K. (2008) · Der Hautarzt · doi:10.1007/s00105-008-1530-2 · Cited by 26
Wong, C. F. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl573 · Cited by 26
“Unfortunately, in up to 10% of patients, disease remains refractory despite conventional therapy [1].”
BackgroundSmall‐vessel and medium‐vessel vasculitis
Seo, P., & Stone, J. H. (2007) · Arthritis Care & Research · doi:10.1002/art.23105 · Cited by 28
“This strategy was examined in CYCAZAREM (Cyclophosphamide or Azathioprine as a Remission therapy for vasculitis), a prospective, randomized, multicenter study conducted by the European Vasculitis Study Group (24).”
BackgroundMethodLittle, M. A., & Pusey, C. D. (2005) · Nephrology · doi:10.1111/j.1440-1797.2005.00434.x · Cited by 26
Self-citationUpdate on the Treatment of Granulomatosis with Polyangiitis (Wegener’s)
Langford, C. A. (2012) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-012-0165-x · Cited by 25
The European Vasculitis Society 2016 Meeting Report
Bajema, I. M., Bruijn, J. A., Casian, A., Cid, M. C., Csernok, E., van Daalen, E., Harper, L., Hauser, T., Little, M. A., Luqmani, R. A., et al. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.09.008 · Cited by 28
Self-citationSpeer, C., Altenmüller-Walther, C., Splitthoff, J., Nußhag, C., Kälble, F., Reichel, P., Morath, C. P., Zeier, M., Bergner, R., & Schaier, M. (2020) · Rheumatology International · doi:10.1007/s00296-020-04752-9 · Cited by 25
“In a recently published prospective study including 49 patients with severe AAV [22], the effectiveness of an early GC withdrawal within 7–14 days in combination with low-dose CYC and two 1 g doses of RTX was comparable to effectiveness in matched controls (n = 172) from previous EUVAS trials (CYCAZAREM [23], CYCLOPS…”
ResultTreatment of granulomatosis with polyangiitis (Wegener’s)
Pagnoux, C., & Guillevin, L. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1008455 · Cited by 25
“The staged-treatment approach, with induction based on the combination of glucocorticoids and cyclophosphamide, followed by maintenance, based on less toxic agents such as azathioprine or methotrexate started as soon as remission is obtained, was the subsequent major therapeutic advance [37,42].”
BackgroundAouba, A., Pagnoux, C., Bienvenu, B., Mahr, A., & Guillevin, L. (2007) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-8026-1 · Cited by 25
Plasmapheresis in nephrology: an update
Rahman, T., & Harper, L. (2006) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000247503.87162.15 · Cited by 25
Advances in the treatment of ANCA-associated vasculitis
Trivioli, G., Moura, M. C., Kronbichler, A., Smith, R., Terrier, B., McAdoo, S. P., Jones, R. B., Merkel, P. A., & Jayne, D. R. W. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01266-1 · Cited by 28
Self-citationTreatment Updates in Antineutrophil Cytoplasmic Autoantibodies (ANCA) Vasculitis
Jain, K., Jawa, P., Derebail, V. K., & Falk, R. J. (2021) · Kidney360 · doi:10.34067/kid.0007142020 · Cited by 27
“The cyclophosphamide or azathioprine as a remission therapy for vasculitis (CYCAZAREM) trial demonstrated that azathioprine could safely replace oral cyclophosphamide for maintenance without increasing the relapse rate (46).”
BackgroundVassilopoulos, A., Vassilopoulos, S., Kalligeros, M., Shehadeh, F., & Mylonakis, E. E. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1110548 · Cited by 30
Chen, D., Lian, F., Yuan, S., Wang, Y., Zhan, Z., Ye, Y., Qiu, Q., Xu, H., Liang, L., & Yang, X. (2013) · Clinical Rheumatology · doi:10.1007/s10067-013-2441-x · Cited by 24
“Recent studies demonstrated that AZA was the most preferred choice for remission maintenance in SLE patients [2].”
BackgroundLong-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis
Nagafuchi, H., Atsumi, T., Hatta, K., Muso, E., Takeno, M., Yamada, H., & Ozaki, S. (2014) · Modern Rheumatology · doi:10.3109/14397595.2014.981945 · Cited by 24
“Complete remission was defi ned as a BVAS score of 0 or 1, indicating the absence of signs of new or worsening disease activity [4].”
BackgroundTherapy for Vasculitic Neuropathies
Gorson, K. C. (2006) · Current Treatment Options in Neurology · doi:10.1007/s11940-006-0002-1 · Cited by 24
Improving Outcomes in Patients with Lupus and End‐Stage Renal Disease
Inda-Filho, A. J., Neugarten, J., Putterman, C., & Broder, A. R. (2013) · Seminars in Dialysis · doi:10.1111/sdi.12122 · Cited by 26
Monti, S. M., Quinn, K. A., Christensen, R., Jayne, D. R. W., Langford, C. A., Lanier, G. E., Mahr, A., Pagnoux, C., Viðarsdóttir, M. B., Merkel, P. A., et al. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.09.010 · Cited by 24
Self-citationImmunosuppressive treatment for non-systemic vasculitic neuropathy
Vrancken, A. F. J. E., Hughes, R. A., Saïd, G., Wokke, J. H. J., & Notermans, N. C. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006050.pub2 · Cited by 26
Renal manifestations of systemic autoimmune disease: diagnosis and therapy
O’Callaghan, C. A. (2004) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2004.03.002 · Cited by 24
Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies
Goek, O. N., & Stone, J. H. (2005) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000160777.28259.c2 · Cited by 24
de Joode, A. A. E., Sanders, J., Rutgers, A., & Stegeman, C. A. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu397 · Cited by 23
ANCA-associated vasculitides: Pathogenetic aspects and current evidence-based therapy
Holle, J. U., & Gross, W. L. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.02.019 · Cited by 23
Self-citationWegener Granulomatosis (Granulomatosis with Polyangiitis): Evolving Concepts in Treatment
Lynch, J. P., & Tazelaar, H. D. (2011) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0031-1279825 · Cited by 24
Vasculitis in the gastrointestinal tract
Morgan, M. D., & Savage, C. O. S. (2005) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2004.11.010 · Cited by 22
Evidence-based management of ANCA vasculitis
Carruthers, D. M., & Sherlock, J. P. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2008.12.003 · Cited by 23
Pavlakis, P. P., & Dalakas, M. C. (2011) · Springer eBooks · doi:10.1007/978-0-85729-947-5_21 · Cited by 23
Emerging therapies in antineutrophil cytoplasm antibody-associated vasculitis
Furuta, S., & Jayne, D. R. W. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000005 · Cited by 24
“and cyclophosphamide for remission induction followed by azathioprine or methotrexate maintenance therapy [2,3].”
BackgroundSelf-citationRituximab in the Treatment of Anti-Neutrophil Cytoplasm Antibody-Associated Vasculitis
Jones, R. B. (2014) · Nephron Clinical Practice · doi:10.1159/000368580 · Cited by 22
Roccatello, D., Sciascia, S., Rossi, D., Alpa, M., Naretto, C., Radin, M., Fenoglio, R., Baldovino, S., & Menegatti, E. (2017) · Oncotarget · doi:10.18632/oncotarget.18120 · Cited by 22
“When focusing on risk factors for relapses, several studies have shown that relapses are much more frequent in patients with PR3-AAV than in those with MPO-AAV, and PR3-ANCA positivity is often the most important risk factor for relapses in multivariate analyses [13-17].”
Necrotizing Arteritis and Small-Vessel Vasculitis
Alba, M. A., Jennette, J. C., & Falk, R. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00065-8 · Cited by 22
Sinclair, D., & Stevens, J. M. (2007) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/000456307781646049 · Cited by 22
Frankel, S. K., & Jayne, D. R. W. (2010) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2010.04.005 · Cited by 25
Self-citationLinder, R., ORTH, I., HAGEN, E. C., van der Woude, F. J., & Schmitt, W. H. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.100814 · Cited by 26
Self-citationHara, A., Wada, T., Sada, K., Amano, K., Dobashi, H., Harigai, M., Takasaki, Y., Yamada, H., Hasegawa, H., Hayashi, T., et al. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.170508 · Cited by 22
Shobha, V., Fathima, S., & Prakash, R. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-018-0492-7 · Cited by 22
“With this treatment regimen, initial remission rates of 70-90% have been reported [2] [3] [4] .”
BackgroundLong-term damage to the ENT system in Wegener’s granulomatosis
Pero, M. M. D., Walsh, M. W., Luqmani, R. A., Floßmann, O., Mukhtyar, C. B., Jani, P., Rasmussen, N., & Jayne, D. R. W. (2010) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-010-1421-x · Cited by 22
“The criteria used to diagnose WG were adapted from the classification criteria of the American College of Rheumatology and the definitions from the Chapel Hill Consensus Conference [4, 13, 16].”
MethodSelf-citationSmall vessel vasculitis of the lung
Frankel, S. K., Cosgrove, G. P., & Brown, K. K. (2005) · Chronic Respiratory Disease · doi:10.1191/1479972305cd070rs · Cited by 22
Update on Wegener granulomatosis.
Langford, C. A. (2005) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.72.8.689 · Cited by 22
Sangle, S. R., Hughes, G. R. V., & D’Cruz, D. P. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.065623 · Cited by 22
Vasculopathy and pulmonary arterial hypertension
Guillevin, L. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/ken484 · Cited by 22
Cao, Y., Tian, Z., Li, W., Ma, L., Yu, Y., & Ren, W. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130758 · Cited by 22
The linkage between Churg-Strauss syndrome and leukotriene receptor antagonists: fact or fiction?
McDanel, D. L., & Muller, B. A. (2005) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.1.2.125.62913 · Cited by 24
“The doses used for AZA in CSS are similar to what is used in Wegener’s granulo-matosis, and in most patients azathioprine is initially given at a dose of 2 mg/kg/d (Jayne et al 2003).”
Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
Floßmann, O., Jones, R. B., Jayne, D. R. W., & Luqmani, R. A. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.048900 · Cited by 22
Self-citationHallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist
Lee, J. J. Y., AlSaleem, A., Chiang, G. P. K., Limenis, E., Sontichai, W., Yeung, R. S. M., Akikusa, J., & Laxer, R. M. (2019) · Pediatric Rheumatology · doi:10.1186/s12969-019-0343-4 · Cited by 23
Gordon, M. A., Grafton‐Clarke, C., Akobeng, A. K., MacDonald, J. K., Chande, N., Hanauer, S. B., & Arnott, I. D. (2020) · Frontline Gastroenterology · doi:10.1136/flgastro-2020-101405 · Cited by 27
Xiao, Y., Guyatt, G. H., Zeng, L., Jayne, D. R. W., Merkel, P. A., Siemieniuk, R. A. C., Dookie, J., Buchan, T. A., Ahmed, M. M., Couban, R., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-050507 · Cited by 28
“An important general rule is that in routine clinical practice, the use of conventional GC should be ‘as much as necessary, but as little as possible’.”
BackgroundSelf-citationANCA-associated vasculitis: from bench research to novel treatments
Pallan, L., Savage, C. O. S., & Harper, L. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.45 · Cited by 23
Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial
Specks, U., Merkel, P. A., Hoffman, G. S., Langford, C. A., Spiera, R., Seo, P., Kallenberg, C. G. M., Clair, E. W. S., Ding, L., Webber, L., et al. (2011) · The Open Arthritis Journal · doi:10.2174/1876539401104010001 · Cited by 21
“The primary outcome analysis, reported in 2010, compared conventional therapy (the combination of cyclophosphamide (CYC) and glucocorticoids) to the combination of rituximab (RTX) and glucocorticoids.”
BackgroundBajema, I. M. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04359.x · Cited by 21
Clinical course and outcomes of childhood-onset granulomatosis with polyangiitis.
James, K. E., Xiao, R., Merkel, P. A., & Weiss, P. F. (2017) · PubMed · Cited by 21
Polyarteritis Nodosa Resistant to Conventional Treatment in a Pediatric Patient
González-Fernández, M. Á., & García-Consuegra, J. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h637 · Cited by 21
Vasculitis treatment – new therapeutic approaches
Dillon, M. J. (2006) · European Journal of Pediatrics · doi:10.1007/s00431-005-0070-3 · Cited by 21
Shi, Y., Li, Z., Zhao, M., & Chen, M. (2015) · Medicine · doi:10.1097/md.0000000000000843 · Cited by 21
Methotrexate for Wegener's granulomatosis: What is the evidence?
Specks, U. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21146 · Cited by 21
Metadata
- Authors
- Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., Gross, W., Hagen, E. C., Mirapeix, E., Pettersson, E., Siegert, C., Sinico, A., Tesar, V., Westman, K., & Pusey, C.
- Affiliations
- Addenbrooke's Hospital (GB)
- Rigshospitalet (DK)
- University of Birmingham (GB)
- Maastricht University (NL)
- University of Helsinki (FI)
- Imperial College London (GB)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Lübeck (DE)
- Hospital Clínic de Barcelona (ES)
- Leiden University Medical Center (NL)
- Azienda Ospedaliera Ospedale San Carlo Borromeo (IT)
- Lund University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-03
- Volume
- 349
- Issue
- 1
- Pages
- 36-44
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1981535363
- Cited by
- 1,348
- References
- 44
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 24 · 2023: 37 · 2022: 48 · 2021: 36 · 2020: 51 · 2019: 46 · 2018: 51 · 2017: 46 · 2016: 51 · 2015: 80 · 2014: 77 · 2013: 80 · 2012: 83
- FWCI
- 48.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Keywords
- ANCA-associated vasculitis, maintenance therapy, cyclophosphamide, azathioprine, granulomatosis with polyangiitis, microscopic polyangiitis, relapse, remission, prednisolone, adverse events
- MeSH terms
- Adult, Aged, Azathioprine, Cyclophosphamide, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunosuppressive Agents, Male, Middle Aged, Neutropenia, Prednisolone, Recurrence, Remission Induction, Vasculitis, Antibodies, Antineutrophil Cytoplasmic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.